Clinical Department No 10, General Surgery, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.
Department of Oncological Surgery, Oncological Institute "Prof. Dr. Alexandru Trestioreanu", 022328 Bucharest, Romania.
Medicina (Kaunas). 2024 May 26;60(6):871. doi: 10.3390/medicina60060871.
: Cervical cancer is the fourth most frequent type of neoplasia in women. It is most commonly caused by the persistent infection with high-risk strands of human papillomavirus (hrHPV). Its incidence increases rapidly from age 25 when routine HPV screening starts and then decreases at the age of 45. This reflects both the diagnosis of prevalent cases at first-time screening and the likely peak of HPV exposure in early adulthood. For early stages, the treatment offers the possibility of fertility preservation.. However, in more advanced stages, the treatment is restricted to concomitant chemo-radiotherapy, combined, in very selected cases with surgical intervention. After the neoadjuvant treatment, an imagistic re-evaluation of the patients is carried out to analyze if the stage of the disease remained the same or suffered a downstaging. Lymph node downstaging following neoadjuvant treatment is regarded as an indubitable prognostic factor for predicting disease recurrence and survival in patients with advanced cervical cancer. This study aims to ascertain the important survival role of radiotherapy in the downstaging of the disease and of lymphadenectomy in the control of lymph node invasion for patients with advanced-stage cervical cancer. : We describe the outcome of patients with cervical cancer in stage IIIC1 FIGO treated at Bucharest Oncological Institute. All patients received radiotherapy and two-thirds received concomitant chemotherapy. A surgical intervention consisting of type C radical hysterectomy with radical pelvic lymphadenectomy was performed six to eight weeks after the end of the neoadjuvant treatment. : The McNemar test demonstrated the regression of lymphadenopathies after neoadjuvant treatment-: <0.001. However, the persistence of adenopathies was not related to the dose of irradiation (: 0.61), the number of sessions of radiotherapy (: 0.80), or the chemotherapy (: 0.44). Also, there were no significant differences between the adenopathies reported by imagistic methods and those identified during surgical intervention-: 0.62. The overall survival evaluated using Kaplan-Meier curves is dependent on the post-radiotherapy FIGO stage-: 0.002 and on the lymph node status evaluated during surgical intervention-: 0.04. The risk factors associated with an increased risk of death were represented by a low preoperative hemoglobin level (: 0.003) and by the advanced FIGO stage determined during surgical intervention (-value: 0.006 for stage IIIA and 0.01 for stage IIIC1). In the multivariate Cox model, the independent predictor of survival was the preoperative hemoglobin level (: 0.004, HR 0.535, CI: 0.347 to 0.823). Out of a total of 33 patients with neoadjuvant treatment, 22 survived until the end of the study, all 33 responded to the treatment in varying degrees, but in 3 of them, tumor cells were found in the lymph nodes during the intraoperative histopathological examination. : For advanced cervical cancer patients, radical surgery after neoadjuvant treatment may be associated with a better survival rate. Further research is needed to identify all the causes that lead to the persistence of adenopathies in certain patients, to decrease the FIGO stage after surgical intervention, and, therefore, to lower the risk of death. Also, it is mandatory to correctly evaluate and treat the anemia, as it seems to be an independent predictor factor for mortality.
宫颈癌是女性第四大常见的肿瘤类型。它通常由高危型人乳头瘤病毒(HPV)持续感染引起。从 25 岁开始进行常规 HPV 筛查时,其发病率迅速上升,然后在 45 岁时下降。这既反映了首次筛查时普遍病例的诊断,也反映了 HPV 在成年早期暴露的可能高峰。对于早期阶段,治疗提供了保留生育能力的可能性。然而,在更晚期,治疗仅限于联合化疗放疗,在非常选定的情况下,结合手术干预。新辅助治疗后,对患者进行影像学重新评估,以分析疾病的阶段是否保持不变或是否出现降级。新辅助治疗后淋巴结降级被认为是预测晚期宫颈癌患者疾病复发和生存的明确预后因素。本研究旨在确定放疗在疾病降级和淋巴结切除术在控制晚期宫颈癌淋巴结侵犯方面的重要生存作用。
我们描述了布加勒斯特肿瘤研究所治疗的 IIIC1FIGO 期宫颈癌患者的结局。所有患者均接受放疗,三分之二的患者接受了同期化疗。在新辅助治疗结束后六至八周,进行包括 C 型根治性子宫切除术和根治性盆腔淋巴结切除术的手术干预。
McNemar 检验显示新辅助治疗后淋巴结病消退:<0.001。然而,淋巴结病的持续存在与照射剂量无关(:0.61),放疗次数(:0.80)或化疗(:0.44)无关。此外,影像学方法报告的淋巴结病与手术干预中识别的淋巴结病之间没有显著差异:0.62。使用 Kaplan-Meier 曲线评估的总生存率取决于放疗后的 FIGO 分期:0.002 和手术干预期间评估的淋巴结状态:0.04。与死亡风险增加相关的危险因素包括术前血红蛋白水平低(:0.003)和术中确定的高级 FIGO 分期(-值:III 期 A 为 0.006,IIIC1 期为 0.01)。在多变量 Cox 模型中,生存的独立预测因素是术前血红蛋白水平(:0.004,HR 0.535,CI:0.347 至 0.823)。在总共 33 名接受新辅助治疗的患者中,有 22 名患者存活至研究结束,所有 33 名患者均在不同程度上对治疗有反应,但其中 3 名患者在术中组织病理学检查中发现淋巴结中有肿瘤细胞。
对于晚期宫颈癌患者,新辅助治疗后行根治性手术可能与生存率的提高相关。需要进一步研究以确定导致某些患者淋巴结病持续存在的所有原因,降低手术干预后的 FIGO 分期,从而降低死亡风险。此外,必须正确评估和治疗贫血,因为它似乎是死亡率的独立预测因素。